Paul J Kenny, PhD
- PROFESSOR & CHAIR | Neuroscience
- DIRECTOR, DRUG DISCOVERY INSTITUTE
Research Topics:
Addiction, Behavior, Brain, Drug Design and Discovery, Epigenetics, Gene Expressions, Molecular Biology, Neurobiology, Neuroscience, Obesity, Schizophrenia
Paul J. Kenny, PhD, is Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience. Dr. Kenny also serves as the Director of the Drug Discovery Institute. His multidisciplinary research involves the study of behavioral paradigms, physiological analyses, and the molecular underpinnings of neurobehavioral disorders. Dr. Kenny is actively investigating the brains of rodents to uncover new signaling cascades that may play a role in addiction-like behaviors. The Kenny Laboratory is focused on understanding the neurobiological mechanisms of drug addiction, obesity and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors (nAChRs) in these processes. They employ a multidisciplinary approach that includes complex behavioral paradigms, physiological analyses and molecular biological techniques. Current projects include the utilization of vector-based delivery systems to modify gene expression in the brains of rodents to identify novel signaling cascades that may play a role in addiction-like behaviors. Search PubMed for articles
Contact
Nora McLaughlin
Executive Assistant to Paul Kenny
Phone: 212-824-8968 or ext. 58968
Email: nora.mclaughlin@mssm.edu
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS], Pharmacology and Therapeutics Discovery [PTD]Education
BA, Trinity College Dublin
PhD, University of London
-
2020
Annual Alton Ochsner Award Relating Smoking and Disease -
2018
Daniel H. Efron Research Award -
2015
Tom Connor Distinguished Investigator Award -
2012
Mathilde Solowey Lecture Award in the Neurosciences -
2010
Jacob P. Waletzky Memorial Award
The Kenny Laboratory is focused on understanding the neurobiological mechanisms of drug addiction, obesity and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors (nAChRs) in these processes. They employ a multidisciplinary approach that includes complex behavioral paradigms, physiological analyses and molecular biological techniques. Current projects include the utilization of vector-based delivery systems to modify gene expression in the brains of rodents to identify novel signaling cascades that may play a role in addiction-like behaviors. Search PubMed for articles
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kenny during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- AstraZeneca; EpiVario
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Eolas Therapeutics, Inc.
Royalty Payments:
- Eolas Therapeutics, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.